Pharmacology and neuroprotective actions of mGlu receptor ligands.
O'Neill
M J
MJ
Eli Lilly & Co. Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, England.
D000596:Amino Acids / Q000494:pharmacology; D001921:Brain / Q000187:drug effects*; D002545:Brain Ischemia / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology; D003521:Cyclopropanes / Q000494:pharmacology / Q000627:therapeutic use; D005998:Glycine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007608:Kainic Acid / Q000009:adverse effects / Q000037:antagonists & inhibitors; D008024:Ligands; D009410:Nerve Degeneration / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control; D018696:Neuroprotective Agents / Q000494:pharmacology*; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000596:Amino Acids; D001643:Bridged Bicyclo Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D003521:Cyclopropanes; C118218:LY 379268; C118219:LY 389795; D008024:Ligands; D018696:Neuroprotective Agents; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate; C108822:metabotropic glutamate receptor 2; C102718:metabotropic glutamate receptor 3; C113897:metabotropic glutamate receptor 6; C102719:metabotropic glutamate receptor 7; C111435:metabotropic glutamate receptor 8; C104077:metabotropic glutamate receptor type 1; C082313:2-(2,3-dicarboxycyclopropyl)glycine; C104753:eglumetad; D007608:Kainic Acid; D005998:Glycine